Agilent Technologies (A) Valuation Check After CRISPR Patent Loss And BioTek Cytation 9 Launch

Simply Wall St.04-15

Agilent Technologies (A) is back in focus after two contrasting developments: the Supreme Court left rulings invalidating its CRISPR related patents in place, and the company introduced its new BioTek...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627447004?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/154924-main-header/1756254020530","is_english":true,"pubTime":"2026-04-15 11:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627447004","market":"hk","top_or_hot":-1,"title":"Agilent Technologies (A) Valuation Check After CRISPR Patent Loss And BioTek Cytation 9 Launch","media":"Simply Wall St.","content":"<div>\n<p>Agilent Technologies (A) is back in focus after two contrasting developments: the Supreme Court left rulings invalidating its CRISPR related patents in place, and the company introduced its new BioTek...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-technologies-a-valuation-check-after-crispr-patent-l\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent Technologies (A) Valuation Check After CRISPR Patent Loss And BioTek Cytation 9 Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent Technologies (A) Valuation Check After CRISPR Patent Loss And BioTek Cytation 9 Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-15 11:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-technologies-a-valuation-check-after-crispr-patent-l><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agilent Technologies (A) is back in focus after two contrasting developments: the Supreme Court left rulings invalidating its CRISPR related patents in place, and the company introduced its new BioTek...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-technologies-a-valuation-check-after-crispr-patent-l\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-technologies-a-valuation-check-after-crispr-patent-l","article_id":"2627447004","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/154924-main-header/1756254020530"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-technologies-a-valuation-check-after-crispr-patent-l","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627447004","pubTimestamp":1776222464,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Agilent Technologies (A) is back in focus after two contrasting developments: the Supreme Court left rulings invalidating its CRISPR related patents in place, and the company introduced its new BioTek Cytation 9 cell imaging multimode reader.\nSee our latest analysis for Agilent Technologies.\nAt a share price of $120.39, investors have seen a 7.96% 1 month share price return and a 5.72% 7 day gain. However, the 90 day share price return of 17.50% and year to date share price return of 12.73%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","CRSP":"CRISPR Therapeutics AG","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","A":"安捷伦科技","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","LU1543694498.USD":"法巴水资源基金RH MD Dis","LU1861558580.USD":"日兴方舟颠覆性创新基金B","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4611":"AI医疗","BK4139":"生物科技","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","BK4588":"碎股","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis"},"translate_title":"安捷伦科技(A)CRISPR专利丢失和BioTek Cytation 9推出后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1.5,"A":1.5},"content_text":"Agilent Technologies (A) is back in focus after two contrasting developments: the Supreme Court left rulings invalidating its CRISPR related patents in place, and the company introduced its new BioTek Cytation 9 cell imaging multimode reader. See our latest analysis for Agilent Technologies. At a share price of $120.39, investors have seen a 7.96% 1 month share price return and a 5.72% 7 day gain. However, the 90 day share price return of 17.50% and year to date share price return of 12.73% point to fading momentum despite a 1 year total shareholder return of 17.71%. If the patent ruling and new product launch have you rethinking exposure to life sciences and diagnostics, it can be useful to compare Agilent with other healthcare related AI names through 34 healthcare AI stocks With the stock at $120.39, trailing a 17.5% 90 day share price decline but sitting at about a 3% intrinsic discount and a 33% gap to analyst targets, is this a reset that opens a buying window, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 26% Undervalued At $120.39, the most followed narrative anchors Agilent's fair value around $161.94, implying a sizeable valuation gap that rests on specific growth and margin assumptions.  Strategic investments in higher margin recurring revenue streams, including consumables, software, services, and digital platforms, are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.  Read the complete narrative. Read the complete narrative. Curious what kind of revenue growth, margin expansion, and earnings profile are built into that fair value and price target spread? The narrative outlines a detailed path for sales, profitability, and valuation multiples that may be different from what you might infer by only looking at recent share price moves. Result: Fair Value of $161.94 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on tariffs and supply chain costs not rising more than expected, and on capital equipment replacement cycles not slowing beyond what analysts currently anticipate. Find out about the key risks to this Agilent Technologies narrative. Next Steps With the mood split between patent setbacks and valuation upside, it helps to look at the underlying data yourself and decide quickly where you stand. To see what optimists are focusing on, review the 4 key rewards. Ready for more investment ideas? If Agilent has sharpened your focus, do not stop here. Widen your watchlist with a few targeted ideas that other investors could overlook.  Target potential mispricings by scanning a curated list of value opportunities through the 57 high quality undervalued stocks. Strengthen your income stream by reviewing companies that feature resilient payouts via the 12 dividend fortresses. Reduce unnecessary surprises by focusing on companies that score well on stability using the 74 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627447004","isCrawlerRequest":true}